PTC Therapeutics 8-K: Officer Changes, Comp Arrangements
Ticker: PTCT · Form: 8-K · Filed: Mar 25, 2026 · CIK: 0001070081
| Field | Detail |
|---|---|
| Company | Ptc Therapeutics, Inc. (PTCT) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2026 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $50,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**PTC Therapeutics just filed an 8-K about executive changes and pay, watch for details.**
AI Summary
PTC Therapeutics, Inc. filed an 8-K on March 25, 2026, reporting on events from March 24, 2026. The filing specifically addresses Item 5.02, which covers changes in directors or officers and their compensation arrangements, and Item 7.01, related to Regulation FD Disclosure. This matters to investors because changes in leadership or executive compensation can signal shifts in company strategy, financial health, or future performance, potentially impacting the stock's value.
Why It Matters
Changes in executive leadership or compensation can significantly influence a company's direction and investor confidence, directly affecting stock performance.
Risk Assessment
Risk Level: medium — The filing indicates changes in officers and their compensation, which can introduce uncertainty regarding future leadership and financial commitments, warranting a medium risk assessment.
Analyst Insight
Investors should seek out the specific details of the officer changes and compensation arrangements mentioned in Item 5.02, as these could indicate strategic shifts or financial implications for PTC Therapeutics, Inc. Further investigation into the EX-99.1 exhibit might provide more context.
Key Players & Entities
- PTC THERAPEUTICS, INC. (company) — Filer of the 8-K
- 0001070081 (company) — CIK of PTC Therapeutics, INC.
- 2026-03-25 (date) — Filing Date
- 2026-03-24 (date) — Period of Report
FAQ
What specific items were reported in this 8-K filing by PTC Therapeutics, Inc.?
This 8-K filing by PTC Therapeutics, Inc. reported on Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, and Item 7.01: Regulation FD Disclosure, as well as Item 9.01: Financial Statements and Exhibits.
When was this 8-K filing accepted by the SEC?
The 8-K filing was accepted by the SEC on 2026-03-25 at 09:00:38.
What is the CIK number for PTC Therapeutics, Inc.?
The CIK number for PTC Therapeutics, Inc. is 0001070081.
What is the business address of PTC Therapeutics, Inc. as listed in the filing?
The business address of PTC Therapeutics, Inc. is 500 WARREN CORPORATE CENTER DRIVE, WARREN NJ 07059.
What is the SIC code for PTC Therapeutics, Inc. and what does it represent?
The SIC code for PTC Therapeutics, Inc. is 2834, which represents Pharmaceutical Preparations.
Filing Stats: 1,127 words · 5 min read · ~4 pages · Grade level 11.2 · Accepted 2026-03-25 09:00:38
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo
- $50,000 — ctor receives a base annual retainer of $50,000 per year for service as a Board member.
Filing Documents
- tmb-20260324x8k.htm (8-K) — 49KB
- tmb-20260324xex99d1.htm (EX-99.1) — 12KB
- 0001104659-26-034207.txt ( ) — 179KB
- tmb-20260324.xsd (EX-101.SCH) — 3KB
- tmb-20260324_def.xml (EX-101.DEF) — 3KB
- tmb-20260324_lab.xml (EX-101.LAB) — 16KB
- tmb-20260324_pre.xml (EX-101.PRE) — 9KB
- tmb-20260324x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 25, 2026, the Company issued a press release in which it announced the appointment of Ms. Chutter described above. A copy of the press release is attached to this Current Report on Form 8-K (this "Report") as Exhibit 99.1 and is incorporated by reference into this Item 7.01. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 2 5 , 2026 issued by PTC Therapeutics, Inc. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: March 25, 2026 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer